# Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA

> **NCT02528318** · PHASE2 · TERMINATED · sponsor: **Windtree Therapeutics** · enrollment: 48 (actual)

## Conditions studied

- Respiratory Distress Syndrome

## Interventions

- **COMBINATION_PRODUCT:** Lucinactant for inhalation
- **DEVICE:** nCPAP alone

## Key facts

- **NCT ID:** NCT02528318
- **Lead sponsor:** Windtree Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-08
- **Primary completion:** 2017-05-31
- **Final completion:** 2017-08-11
- **Target enrollment:** 48 (ACTUAL)
- **Why stopped:** Sponsor decision to terminate after 3 dosing groups
- **Last updated:** 2019-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02528318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02528318, "Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02528318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*